{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T05:03:39Z","timestamp":1769663019012,"version":"3.49.0"},"reference-count":36,"publisher":"Centre for Evaluation in Education and Science (CEON\/CEES)","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/BY\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Med Biochemistry"],"published-print":{"date-parts":[[2026]]},"abstract":"<jats:p>Background: This study aimed to evaluate the association between low-cost inflammatory biomarkers and disease severity in ulcerative colitis (UC), with a focus on predicting acute severe ulcerative colitis (ASUC) and active disease (Mayo score &amp;gt;1). Methods: An analytical cross-sectional study was conducted on 131 patients diagnosed with UC at Imam Khomeini Hospital, Iran, between 2022 and 2024. Demographic, clinical, and laboratory data - including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), CRP-to-albumin ratio (CAR), and faecal calprotectin - were collected. Disease activity was evaluated using the Mayo Endoscopic Score (MES). Statistical analyses included chi-square tests, ANOVA, and multivariable logistic regression adjusted for age, sex, and body mass index (BMI). Results: The mean age of participants was 45.8\u00b1 15.9 years. Elevated inflammatory markers were observed (CRP: 39.1 \u00b1 32.6 mg\/L; ESR: 44 .0\u00b1 21.5 mm\/hr). Defecation frequency S6\/day was significantly associated with ASUC (c2(2) = 101.10, p&amp;lt; 0.001). After adjustment, PLR in the third quartile (14-20) was independently associated with ASUC (O R = 2.57, p= 0.034). The percentage of monocytes was significantly higher in ASUC patients (F(1, 30) = 6.52, p= 0.016). No significant associations were found for NLR or CAR. PLR also differed significantly between active and inactive UC groups (median [ IQR] : 133.87 [96.15-190.63] vs. 129.61 [102.15-209.98], p= 0.029), although its discriminatory power was limited. Conclusions: PLR and monocyte percentage may serve as accessible indicators for assessing UC severity and identifying patients at risk for ASUC. These findings support the supplementary use of routine inflammatory blood indices in the management of UC, especially in resource-limited settings.<\/jats:p>","DOI":"10.5937\/jomb0-58955","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T07:32:12Z","timestamp":1755588732000},"page":"72-80","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of relationship between endoscopic activity index and inflammatory indicators such as fecal calprotectin, C-reactive protein to albumin ratio, neutrophil to lymphocyte ratio, platelet to lymphocyte ratio in ulcerative colitis patients"],"prefix":"10.5937","volume":"45","author":[{"given":"Tarang","family":"Taghvaei","sequence":"first","affiliation":[{"name":"Mazandaran University of Medical Sciences, Gut and Liver Research Centre, Sari, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Seyyed","given":"Hashemi","family":"Abbas","sequence":"additional","affiliation":[{"name":"Mazandaran University of Medical Sciences, Gut and Liver Research Centre, Sari, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iradj","family":"Maleki","sequence":"additional","affiliation":[{"name":"Mazandaran University of Medical Sciences, Gut and Liver Research Centre, Sari, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahboobe","family":"Ebrahimi","sequence":"additional","affiliation":[{"name":"Mazandaran University of Medical Sciences, Gut and Liver Research Centre, Sari, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arash","family":"Kazemi","sequence":"additional","affiliation":[{"name":"Mazandaran University of Medical Sciences, Gut and Liver Research Centre, Sari, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Reyhane","given":"Shahabi","family":"Ebrahimi","sequence":"additional","affiliation":[{"name":"Mazandaran University of Medical Sciences, Gut and Liver Research Centre, Non-Communicable Diseases Institute, Sari, Iran, Department of Microbiology, Ayatollah Amoli Branch, Islamic Azad University, Amol, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jamshid","given":"Charati","family":"Yazdani","sequence":"additional","affiliation":[{"name":"Mazandaran University of Medical Sciences, Department of Biostatistics, Health Sciences Research Centre, Addiction Institute, Sari, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3964","reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Mehdizadeh S, Chen G, Enayati PJ, Cheng DW, Han NJ, Shaye OA, Ippoliti A, Vasiliauskas EA, Lo SK, Papadakis KA. Diagnostic yield of capsule endoscopy in ulcerative colitis and inflammatory bowel disease of unclassified type (IBDU). Endoscopy 2008 Jan; 40(01): 30-5;","DOI":"10.1055\/s-2007-995359"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Romberg-Camps MJ, Hesselink-van de Kruijs MA, Schouten LJ, Dagnelie PC, Limonard CB, Kester AD, Bos LP Goedhard J, Hameeteman WH, Wolters FL, Russel MG. Inflammatory bowel disease in South Limburg (the Netherlands) 1991-2002: incidence, diagnostic delay, and seasonal variations in onset of symptoms. Journal of Crohn's and Colitis 2009 Jun 1; 3(2): 115-24;","DOI":"10.1016\/j.crohns.2008.12.002"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Le Berre C, Danese S, Peyrin-Biroulet L. Can we change the natural course of inflammatory bowel disease?. Therapeutic advances in gastroenterology 2023 Apr; 16: 17562848231163118;","DOI":"10.1177\/17562848231163118"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Le Berre C, Honap S, Peyrin-Biroulet L. Ulcerative colitis. Lancet 2023 Aug 12; 402(10401): 571-84. doi: 10.1016\/S0140-6736(23)00966-2. PMID: 37573077;","DOI":"10.1016\/S0140-6736(23)00966-2"},{"key":"ref5","unstructured":"Choi CH, Jung SA, Lee BI, Lee KM, Kim JS, Han DS. Diagnostic guideline of ulcerative colitis. The Korean journal of gastroenterology= Taehan Sohwagi Hakhoe chi 2009 Mar 1; 53(3): 145-60;"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Waye JD. The role of colonoscopy in the differential diagnosis of inflammatory bowel disease. Gastrointestinal endoscopy 1977 Feb 1; 23(3): 150-4;","DOI":"10.1016\/S0016-5107(77)73622-3"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Jalan KN, Walker RJ, Sircus W, McManus JP Prescott RJ, Card WI. Pseudopolyposis in ulcerative colitis. The Lancet 1969 Sep 13; 294 (7620): 555-9;","DOI":"10.1016\/S0140-6736(69)90260-8"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"D'haens G, Sandborn WJ, Feagan BG, Geboes K, Hanauer SB, Irvine EJ, L\u00e9mann M, Marteau P Rutgeerts P Sch\u00f4lmerich J, Sutherland LR. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007 Feb 1; 132(2): 763-86;","DOI":"10.1053\/j.gastro.2006.12.038"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Schoepfer A, Beglinger C, Straumann A, Trummler M, Renzulli P Seibold F Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes. Inflamm Bowel Dis 2009; 15(12): 1851-8;","DOI":"10.1002\/ibd.20986"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Walsham N, Sherwood R. Fecal calprotectin in inflammatory bowel disease. Clin Exp Gastroenterol 2016; 9: 21-9;","DOI":"10.2147\/CEG.S51902"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Mar\u00e9chal C, Aimone-Gastin I, Baumann C, Dirrenberger B, Gu\u00e9ant J, Peyrin-Biroulet L. Compliance with the faecal calprotectin test in patients with inflammatory bowel disease. United Eur Gastroenterol J 2017; 5(5): 702-7;","DOI":"10.1177\/2050640616686517"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Qin G, Tu J, Liu L, Luo L, Wu J, Tao L, Zhang C, Geng X, Chen X , Ai X , et al. Serum albumin and C-reactive protein\/albumin ratio are useful biomarkers of Crohn's disease activity. Med Sci Monit 2016; 22: 4393-400;","DOI":"10.12659\/MSM.897460"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Puolanne A-M, Kolho K-L, Alfthan H, Ristimaki A, Mustonen H, Farkkila M. Rapid fecal calprotectin test and symptom index in monitoring the disease activity in colonic inflammatory bowel disease. Digestive diseases and sciences 2017; 62: 3123-30;","DOI":"10.1007\/s10620-017-4770-0"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Sarsu SB, Erbagci AB, Ulusal H, Karakus SC, Bulbul OG. The place of calprotectin, lactoferrin, and high-mobility group box 1 protein on diagnosis of acute appendicitis with children. Indian Journal of Surgery 2017; 79: 131-6;","DOI":"10.1007\/s12262-015-1441-2"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Y L, Cheng W, Chen B-q, Lan X , Wang S-d, Wu X-c, et al. Levels of faecal calprotectin and magnetic resonance enterocolonography correlate with severity of small bowel Crohn's disease: a retrospective cohort study. Scientific Reports 2017; 7(1): 1970;","DOI":"10.1038\/s41598-017-02111-6"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Ma L, Pang X, Ji G, Ma X, Li J, Chang Y, Ma C. Application of the neutrophil to lymphocyte ratio in the diagnosis and activity determination of ulcerative colitis: A meta-analysis and systematic review. Medicine 2021 Oct 22; 100(42): e27551;","DOI":"10.1097\/MD.0000000000027551"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Hu X , Li J, Sun Y et al. Combined use of CDAI and blood indices for assessing endoscopic activity in ileocolic Crohn's disease. BMC Gastroenterol 2023; 23(1): 337. doi:10.1186\/s12876-023-02968-0;","DOI":"10.1186\/s12876-023-02968-0"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Danese S, Cde L MC, Fiocchi C. Platelets in inflammatory bowel disease: clinical, pathogenic, and therapeutic implications. Am J Gastroenterol 2004; 99(5): 938-945. doi:10.1111\/j.1572-0241.2004.04129.x;","DOI":"10.1111\/j.1572-0241.2004.04129.x"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Hisamatsu T, Kanai T Mikami Y, Ybneno K, Matsuoka K, Hibi T Immune aspects of the pathogenesis of inflammatory bowel disease. Pharmacol Ther 2013; 137(3): 283-297. doi:10.1016\/j.pharmthera.2012.10.008;","DOI":"10.1016\/j.pharmthera.2012.10.008"},{"key":"ref20","unstructured":"Sayar S, Kurbuz K, Kahraman R, Caliskan Z, Atalay R, Ozturk O, Doganay HL, Ozdil K. A practical marker to determining acute severe ulcerative colitis: CRP\/albumin ratio. Northern clinics of Istanbul 2020 Jan 1; 7(1);"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Liu D, Saikam V, Skrada KA, Merlin D, Iyer SS. Inflammatory bowel disease biomarkers. Med Res Rev 2022; 42(5): 1856-1887. doi:10.1002\/med.21893;","DOI":"10.1002\/med.21893"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Gibson DJ, Hartery K, Doherty J, Nolan J, Keegan D, Byrne K, Martin ST, Buckley M, Sheridan J, Horgan G, Mulcahy HE. CRP\/albumin ratio: an early predictor of steroid responsiveness in acute severe ulcerative colitis. Journal of clinical gastroenterology 2018 Jul 1; 52(6): e48-52;","DOI":"10.1097\/MCG.0000000000000884"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Chen YH , Wang L, Feng SY Cai WM, Chen XF, Huang ZM. The relationship between C reactive protein\/albumin ratio and disease activity in patients with inflammatory bowel disease. Gastroenterology research and practice 2020; 2020(1): 3467419;","DOI":"10.1155\/2020\/3467419"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Dulai PS, Feagan BG, Sands BE, Chen J, Lasch K, Lirio RA. Prognostic Value of Fecal Calprotectin to Inform Treat-to-Target Monitoring in Ulcerative Colitis. Clinical Gastroenterology and Hepatology 2023; 21(2): 456-66.e7;","DOI":"10.1016\/j.cgh.2022.07.027"},{"key":"ref25","unstructured":"Hu T, Zhang Z, Song F Zhang W, Yang J. Evaluation of Mucosal Healing in Ulcerative Colitis by Fecal Calprotectin vs. Fecal Immunochemical Test: A Systematic Review and Meta-analysis. Turk J Gastroenterol 2023; 34(9): 892-901;"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Croft A, Lord A, Radford-Smith G. Markers of Systemic Inflammation in Acute Attacks of Ulcerative Colitis: What Level of C-reactive Protein Constitutes Severe Colitis? Journal of Crohn's and Colitis 2022; 16(7): 1089-96;","DOI":"10.1093\/ecco-jcc\/jjac014"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Rubio-Acosta F Moctezuma-Velazquez P Castro-Romero E, Uscanga-Domfnguez L, Yamamoto-Furusho K, Moctezuma-Velazquez C, et al. The neutrophil-lymphocyte ratio as a predictor of steroid response in patients with severe ulcerative colitis: a retrospective cohort study. Revista espanola de enfermedades digestivas 2023; 115(4): 197-9;","DOI":"10.17235\/reed.2022.9006\/2022"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Celikbilek M, Dogan S, Ozbakir O, Zararsiz G, K\u00fcc\u00fck H, G\u00fcrsoy S, Yurci A, G\u00fcven K, Y\u00fccesoy M. Neutrophil-lymphocyte ratio as a predictor of disease severity in ulcerative colitis. Journal of clinical laboratory analysis. 2013 Jan;27(1):72-6;","DOI":"10.1002\/jcla.21564"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Ge ZB, Zhang XY, Zhang CM, Xu TT, Li SY, Wei MX, Ding XY, Bai CJ, Wang H, Zhou HH, Wang MY C Reactive Protein Is Not the Driver Factor in Ulcerative Colitis. Gastroenterology Research and Practice 2024; 2024(1): 1386147;","DOI":"10.1155\/2024\/1386147"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Ye il A, enate E, Erdem ED, Demirtun\u00e7 R, Ov\u00fcn\u00e7 AO. Red cell distribution width: a novel marker of activity in inflammatory bowel disease. Gut and liver 2011 Nov 21; 5(4): 460;","DOI":"10.5009\/gnl.2011.5.4.460"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Ali S, Zehra A, Khalid MU, Hassan M, Shah SIA. Role of C-reactive protein in disease progression, diagnosis and management. Discoveries (Craiova) 2023 Dec 31; 11(4): e179. doi: 10 .15190\/d .2023.18. PMID: 39554800; PMCID: PMC11569793;","DOI":"10.15190\/d.2023.18"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Masoumi M, Bozorgi M, Nourmohammadi Z, Mousavi MJ, Shariati A, Karami J. Evaluation of hematological markers as prognostic tools in rheumatoid arthritis. BMC Rheumatol 2024 Dec 26. 8(1)75. doi: 10.1186\/ s41927-024-00444-0. PMID: 39722051; PMCID: PMC11670421;","DOI":"10.1186\/s41927-024-00444-0"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Tian Y Zong Y Pang Y Zheng Z, Ma Y Zhang C, Gao J. Platelets and diseases: signal transduction and advances in targeted therapy. Signal Transduct Target Ther 2025 May 16; 10(1): 159. doi: 10.1038\/s41392-025-02198-8. PMID: 40374650; PMCID: PMC12081703;","DOI":"10.1038\/s41392-025-02198-8"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Ludwig N, Hilger A, Zarbock A, Rossaint J. Platelets at the Crossroads of Pro-Inflammatory and Resolution Pathways during Inflammation. Cells 2022 Jun 17; 11(12): 1957. doi: 10.3390\/cells11121957. PMID: 35741086; PMCID: PMC9221767;","DOI":"10.3390\/cells11121957"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Ke Y Liu X , Niu T Qiang Z, Gao F MIR-21 regulating distribution of intestinal flora through TNF-a promotes progression of ulcerative colitis J Med Biochem 2024; 43 (2): 299-305;","DOI":"10.5937\/jomb0-43320"},{"key":"ref36","unstructured":"Zhan C, Tang T, Wu E, Zhang Y, He M, Wu R, Bi C, Wang J, Zhang Y Shen B. From multi-omics approaches to personalised medicine in myocardial infarction. Front Cardiovasc Med 2023 Oct 30; 10: 1250340. doi: 10 .33 89\/fcvm .2023.1250340. PMID: 37 965091; PMCID: PM C10642346;"}],"container-title":["Journal of Medical Biochemistry"],"original-title":["Procena odnosa izme\u0111u endoskopskog indeksa aktivnosti i inflamatornih pokazatelja kao \u0161to su fekalni kalprotektin, odnos c-reaktivnog proteina i albumina, odnos neutrofila i limfocita, odnos trombocita i limfocita kod pacijenata sa ulceroznim kolitisom"],"language":"en","link":[{"URL":"https:\/\/scindeks-clanci.ceon.rs\/data\/pdf\/1452-8258\/2026\/1452-82582601072T.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T17:57:39Z","timestamp":1769623059000},"score":1,"resource":{"primary":{"URL":"https:\/\/scindeks.ceon.rs\/Article.aspx?artid=1452-82582601072T"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5937\/jomb0-58955","relation":{},"ISSN":["1452-8258","1452-8266"],"issn-type":[{"value":"1452-8258","type":"print"},{"value":"1452-8266","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]}}}